Background
Neonatal ART has enabled virologic control and remission in children with in utero HIV-1. We report viral suppression outcomes through 2 years of age in neonates treated with ART with or without VRC01 and the prospect for treatment interruption to assess remission.
Methods
In the ongoing non-randomized, open-label IMPAACT P1115 study, infants ≥36 weeks (wks) gestation and >2 kg at risk for in utero HIV-1 acquisition received 2 NRTIs + nevirapine (NVP) + raltegravir (Regimen 2R) within 48 hours (hrs) of birth. At 2/13 study sites, infants also received VRC01 within 72 hrs of birth (Regimen 2RV). Infants with confirmed in utero HIV-1 continued treatment and follow-up; 2RV infants had additional doses of VRC01 at 2, 6, and 10 wks of age. NVP was stopped 12 wks after 2 consecutive HIV RNA levels <lower limit of quantification (<20 or <40 c/mL). Initial (strict) virologic criteria for consideration of possible treatment interruption at >wk 96 included: no confirmed RNA ≥200 c/mL from wk 24 up to wk 48 and no RNA detected at wk 48 and thereafter. Proportions at each timepoint are described with 2-sided exact 95% binomial confidence intervals (CI) separately by regimen. Cumulative incidence of having no RNA detected at wk 96 was estimated with 95%CI’s.
Results
Of 428 infants initiated on the 2R or 2RV regimen, 24 (17 female) had confirmed in utero HIV-1, 22 continued treatment (2 deaths unrelated to treatment), and 21 (11 2R, 10 2RV) were followed through wk 96 (1 withdrawal). Of these, the fraction [% (CI))] with RNA <200 c/mL at wk 24 was 8/11 on 2R [72.7% (39.5, 94.0%)] and 8/10 on 2RV [80.0% (44.4, 97.5%)]. At wk 24, the fraction [% (CI)] with no RNA detected was 5/11 on 2R [45.5% (16.7, 76.6%)] and 4/10 on 2RV [40.0% (12.2, 73.8%)] and at wk 96, 10/11 on 2R [90.9% (58.7, 99.8%)] and 6/10 on 2RV [60.0% (26.2%, 87.8%)]. The cumulative incidence of having no RNA detected at wk 96 was 72.7% (CI: 32.4, 91.4%) on 2R and 89.9% (CI: 25.1, 99.2%) on 2RV (Figure). Among 8/11 infants on 2R and 7/10 infants on 2RV with RNA <200 c/mL at wks 24 up to wk 48, 4/8 2R and 2/7 2RV had no RNA detected thereafter through wk 96.
Conclusions
Approximately 80% of infants with in utero HIV-1 infection receiving very early ART with or without VRC01 reached virologic control by wk 96. Several of these also met strict virologic criteria through wk 96 for consideration of possible treatment interruption to assess remission. Studies are needed to assess predictors of strict viral suppression in this population.
Table or Figure
